Rufini Sara, Ciccacci Cinzia, Novelli Giuseppe, Borgiani Paola
Department of Biomedicine & Prevention, Genetics Unit, University of Rome "Tor Vergata", Rome, Italy.
Pharmacogenomics. 2017 Jul;18(11):1095-1114. doi: 10.2217/pgs-2017-0068. Epub 2017 Jul 7.
Crohn's disease is an inflammatory bowel disease showing a high heterogeneity in phenotype and a strong genetic component. The treatment is complex, due to different severity of clinical parameters and to the fact that therapies only permit to control symptoms and to induce remission for short periods. Moreover, all categories of drugs present a great interindividual variability both in terms of efficacy and side effects appearance. For this reason, the identification of specific genomic biomarkers involved in drugs response will be of great clinical utility in order to foresee drug's efficacy and to prevent adverse reactions, permitting a more personalized therapeutic approach. In this review, we focus the attention on the pharmacogenetic studies regarding drugs commonly utilized in Crohn's disease treatment.
克罗恩病是一种炎症性肠病，其表型具有高度异质性且有很强的遗传成分。由于临床参数的严重程度不同，以及治疗仅能在短期内控制症状并诱导缓解这一事实，其治疗较为复杂。此外，所有类别的药物在疗效和副作用出现方面都存在很大的个体间差异。因此，识别参与药物反应的特定基因组生物标志物将具有很大的临床实用性，以便预测药物疗效并预防不良反应，从而实现更个性化的治疗方法。在本综述中，我们将注意力集中在关于克罗恩病治疗中常用药物的药物遗传学研究上。
